Phospho-Smad3L promotes progression of hepatocellular carcinoma through decreasing miR-140-5p level and stimulating epithelial-mesenchymal transition

被引:6
|
作者
Hu, Xiangpeng [1 ,2 ]
Han, Dan [3 ,4 ]
Wang, Yanyan [3 ,4 ]
Gu, Jiong [5 ]
Wang, Xian [6 ]
Jiang, Yufeng [2 ]
Yang, Yan [2 ]
Liu, Jun [3 ,4 ,7 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Digest Dept, Hefei, Peoples R China
[2] Anhui Med Univ, Sch Basic Med Coll, Dept Pharmacol, Hefei, Peoples R China
[3] Anhui Med Univ, Sch Basic Med Coll, Dept Pathophysiol, Hefei, Peoples R China
[4] Anhui Med Univ, Biopharmaceut Res Inst, Hefei, Peoples R China
[5] Anhui Med Univ, Affiliated Hosp 2, Dept Gen Surg, Hefei, Peoples R China
[6] Anhui Med Univ, Affiliated Hosp 2, Dept Pathol, Hefei, Peoples R China
[7] Anhui Med Univ, Sch Basic Med Coll, Funct Expt Ctr, Hefei, Peoples R China
关键词
Linker-phosphorylated Smad3; Hepatocellular carcinoma; MircoRNA-140-5p; Epithelial-mesenchymal transition; TGF-BETA; TUMOR-SUPPRESSION; P38; MAPK; GROWTH; ONCOGENESIS; JNK;
D O I
10.1016/j.dld.2021.03.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The transforming growth factor beta (TGF-beta) activates JNK, phosphorylates Smad3 to linkerphosphorylated Smad3 (pSmad3L), resulting in liver tumorigenesis. However, the effect of pSmad3L on hepatocellular carcinoma (HCC) prognosis is obscure. Aim: To detect the effect of pSmad3L on HCC prognosis and investigate the mechanism. Methods: The expressions of pSmad3L, E-cadherin, vimentin and MicroRNA-140-5p (miR-140-5p) were detected by using immunohistochemistry, immunofluorescence and in situ hybridization. Next, the relationships of pSmad3L and HCC patients' prognoses, pSmad3L and EMT markers, pSmad3L and miR-140-5p were analyzed using Spearman's rank correlation test. JNK/pSmad3L specific inhibitor SP600125 or Smad3 mutant plasmid was used to suppress JNK/pSmad3L pathway, and QPCR assay was performed to investigate the effect of pSmad3L on miR-140-5p level. The proliferation and invasion of hepatoma cells were observed using colony formation assay and transwell assay. Results: We demonstrated that patient with high level of pSmad3L predicted poor prognosis. Next, we verified that pSmad3L promoted EMT of hepatoma cells in vivo and in vitro . In order to investigate the mechanism, we verified a negative correlation between pSmad3L and miR-140-5p, which was an EMT inhibitor, in the liver tissues of HCC patient and diethylnitrosamine (DEN)-induced rat HCC model. We further used SP600125 or pSmad3L mutant plasmid to decrease pSmad3L level of hepatoma cells, and inhibition of pSmad3L increased miR-140-5p level and suppressed EMT of hepatoma cells. Conclusions: JNK/pSmad3L pathway induces EMT by inhibiting miR-140-5p in HCC progression. (C) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1343 / 1351
页数:9
相关论文
共 50 条
  • [31] Gelsolin Promotes Cancer Progression by Regulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma and Correlates with a Poor Prognosis
    Zhang, Yixi
    Luo, Xiaojing
    Lin, Jianwei
    Fu, Shunjun
    Feng, Pei
    Su, Hongjun
    He, Xiangjun
    Liang, Xue
    Liu, Kunpeng
    Deng, Wen
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [32] Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling
    Xie, Chun-Feng
    Feng, Kun-Liang
    Wang, Ji-Nan
    Luo, Rui
    Fang, Chong-Kai
    Zhang, Ying
    Shen, Chuang-Peng
    Zhong, Chong
    JOURNAL OF ETHNOPHARMACOLOGY, 2022, 294
  • [33] TGF-β1-Induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p/TGFBR2-SAMD2-SMAD3 Axis
    Yang, Xiaofeng
    Xu, Cuicui
    Liu, Chenghao
    Wu, Xiangwei
    Chen, Xueling
    Hou, Jun
    Wang, Lianghai
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (04)
  • [34] Circ_0084615 promotes epithelial-mesenchymal transition-mediated tumor progression in hepatocellular carcinoma
    Wu, Yu
    Peng, Li
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (06): : 1107 - 1117
  • [35] Hsa_circ_0051908 Promotes Hepatocellular Carcinoma Progression by Regulating the Epithelial-Mesenchymal Transition Process
    Wu, Yinbing
    Tang, Huafei
    Cui, Shuzhong
    Liao, Quanxing
    Zeng, Lisi
    Tu, Yinuo
    ANALYTICAL CELLULAR PATHOLOGY, 2024, 2024
  • [36] ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition
    Xu, Tao
    Zhang, Jian
    Chen, Wei
    Pan, Shengjing
    Zhi, Xiao
    Wen, Liang
    Zhou, Yue
    Chen, Bryan Wei
    Qiu, Junyu
    Zhang, Yun
    Yang, Qi
    Feng, Xinhua
    Bai, Xueli
    Liang, Tingbo
    CANCER LETTERS, 2016, 377 (02) : 140 - 148
  • [37] MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial–mesenchymal transition
    Jie Lin
    Yihui He
    Lingfeng Chen
    Xiaoyan Chen
    Shengbing Zang
    Wansong Lin
    Clinical and Experimental Medicine, 2018, 18 : 523 - 533
  • [38] Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells
    Lv, Hong-Cheng
    Lv, Yan-Yan
    Wang, Gang
    Zhang, Xie-Hua
    Li, Sheng-Nan
    Yue, Xiao-Fen
    Lu, Wei
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2022, 38 (04): : 336 - 346
  • [39] lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p
    Chen, Bryan Wei
    Zhou, Yue
    Wei, Tao
    Wen, Liang
    Zhang, Yi-bo
    Shen, Shi-chao
    Zhang, Jian
    Ma, Tao
    Chen, Wen
    Ni, Lei
    Wang, Yi
    Bai, Xue-li
    Liang, Ting-bo
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (01) : 130 - 142
  • [40] Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway
    Wu H.
    Zhang Z.
    Han X.
    Zhang S.
    Zhang J.
    Han P.
    Zhang Y.
    Bai Y.
    Zhang Y.
    Oxidative Medicine and Cellular Longevity, 2023, 2023